Life Sciences

China is challenging the United States for market share and jobs in one of the highest value-added, most innovation-intensive industries—and the risks extend not just to the U.S. economy, but to global biopharma innovation.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
July 30, 2018
The future of medicine lies in better understanding the human genome and how our bodies function at the most basic level, and that requires reliable and inexpensive genome sequencing. Technological breakthroughs, such as fluorescent labelling and programs capable of reconstructing smaller DNA fragments, massively decreased costs of a full genome sequence to from $300 million in 2000 to $1,500 in 2016.
June 28, 2018
As ITIF’s Stephen Ezell and Richard Owens of the Macdonald Laurier Institute write for the Financial Post, free-riding on drug prices is an example of how Canada refuses to step up to what is required for a globally leading innovation culture.
June 18, 2018
If drug price controls were lifted throughout the OECD, the number of new treatments available would increase 8 to 13 new drug compounds by 2030, writes John Wu in Innovation Files.
May 9, 2018
Please join ITIF for an event discussing needed policies to ensure sustained U.S. life-sciences leadership.
May 7, 2018
Any effective U.S. life-sciences innovation policy needs to level the global playing field by taking more forceful action to address unfair trade practices, Joe Kennedy writes for Stat News.
April 30, 2018
Intellectual property rights go a long way to helping transform clever ideas into life-saving products that address global health challenges, ITIF’s Stephen Ezell and Mark Schultz of the Southern Illinois University School of Law write for Brink News.
April 24, 2018
Twenty-five case studies underscore how innovators in developing countries—often enabled by robust IP rights—are achieving advances in life sciences and healthcare that benefit people around the world.
April 24, 2018
Please join ITIF and the Center for the Protection of Intellectual Property for an event releasing a new report that documents 25 cases of primarily developing-world entrepreneurs meeting global health challenges by “innovating for health.” The event will discuss what policies, including intellectual property, are needed to underpin successful life-sciences innovation in both the developed and developing world and feature presentations from several developing-country healthcare innovators who are leveraging IP, science, and technology to create a better world.
March 26, 2018
America’s lead in life sciences is being challenged. Other countries are aggressively seeking to attract and grow companies with innovation-based tax incentives, a range of firm-specific enticements, increased government research funding, improved IP protections, and streamlined regulatory approval processes. The federal government should act to ensure U.S. life sciences remain competitive.
February 12, 2018
Life-sciences companies grow best in locations that can combine qualities like a good business environment, skilled workers, strong research universities, and available capital. Strengthening these and related factors can give states a stronger competitive advantage.

Pages